Objective-The prevalence of heart failure is increasing in the aging population, and heart failure is a disease with large morbidity and mortality. There is, therefore, a need for identifying modifiable risk factors for prevention. We tested the hypothesis that high concentrations of nonfasting triglycerides and low-density lipoprotein cholesterol are associated with higher risk of heart failure in the general population. Approach and Results-We included 103 860 individuals from the Copenhagen General Population Study and 9694 from the Copenhagen City Heart Study in 2 prospective observational association studies. Nonfasting triglycerides and lowdensity lipoprotein cholesterol were measured at baseline. Individuals were followed for ≤23 years, during which time 3593 were diagnosed with heart failure. Hazard ratios were estimated using Cox proportional hazard regression models.
H eart failure prevalence is increasing in the aging population as the treatment of ischemic heart disease (IHD) and myocardial infarction has improved and as obesity and diabetes mellitus have increased in prevalence. 1, 2 Heart failure is a disease with high morbidity and mortality and with no curable treatment for most patients at present time. It is, therefore, important to improve prevention by identifying modifiable risk factors and treating them.
Previously, we and others have found strong associations between high concentrations of nonfasting triglycerides and risk of myocardial infarction, IHD, all-cause mortality, and ischemic stroke, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] as well as between triglycerides, diabetes mellitus, and heart failure.
1,2 Therefore, high concentrations of nonfasting triglycerides would be expected to be associated with heart failure; however, previous studies of associations between lipids and heart failure have had conflicting results, which could in part be explained by the studies not looking at extreme high concentrations of the lipids but merely dividing individuals into below or above the median, or into quintiles, and thereby not capturing the group of individuals with the highest concentrations. [13] [14] [15] [16] [17] [18] [19] To our knowledge, no study has compared extreme concentrations of nonfasting triglycerides and low-density lipoprotein (LDL) cholesterol head to head with regard to association with risk of heart failure in the general population.
We tested the hypothesis that high concentrations of nonfasting triglycerides and LDL cholesterol are associated with higher risk of heart failure in the general population. For this purpose, 103 860 individuals with 2146 cases of heart failure from the Copenhagen General Population Study (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) were included. Results were confirmed in another cohort from the general Danish population recruited in a different time period (1991) (1992) (1993) (1994) and with minimal use of statins: the Copenhagen City Heart Study with 9694 individuals and 1447 cases of heart failure. Individuals were divided into groups by their concentrations of nonfasting triglycerides and LDL cholesterol using clinically meaningful cut points and capturing extreme high concentrations because it is in these individuals the highest risk of heart failure would be expected.
Materials and Methods
Materials and Methods are in the online-only Data Supplement. Table 1 shows characteristics of individuals in the 2 studies. Individuals in the Copenhagen General Population Study were recruited at a later time period than individuals from the Copenhagen City Heart Study, and therefore, more used lipidlowering therapy and fewer smoked.
Results
Baseline characteristics are also shown for individuals divided by groups of nonfasting triglycerides (Table 2) and by LDL cholesterol (Table I in the online-only Data Supplement). For both higher nonfasting triglycerides and LDL cholesterol, there was a lower percentage women and a larger proportion of individuals with cardiovascular risk factors such as hypertension, smoking, and higher body mass index. In the group with the lowest LDL cholesterol (<3 mmol/L [116 mg/dL]), 22% of individuals used lipidlowering therapy compared with only 2% to 5% in the higher LDL cholesterol groups, which indicates that this group is a combination of individuals with naturally low concentrations of LDL cholesterol and of high-risk individuals using lipidlowering therapy and with previous IHD. To account for this in a sensitivity analysis, LDL cholesterol was multiplied with 1.43 and nonfasting triglycerides with 1.33 for individuals on lipid-lowering therapy corresponding to average reductions of 30% and 25% using common statin treatment regiments, as done previously 20 before dividing individuals into groups (Tables II and III in Figure 1 ). Results from an age-and sex-adjusted analysis were similar. There was no association between stepwise higher LDL cholesterol concentrations and heart failure risk.
Risk of Heart Failure for Higher Nonfasting Triglycerides Stratified by Other Risk Factors
The hazard ratio for heart failure for a 1 mmol/L (88 mg/dL) higher concentration of nonfasting triglycerides was 1.19 (95% CI, 1.12-1.26), which was similar after stratification on conventional risk factors for heart failure ( Figure 2 ) and with no statistical evidence for interactions between nonfasting triglycerides and risk factors on risk of heart failure.
Risk of Heart Failure for Higher LDL Cholesterol Stratified by Other Risk Factors
The hazard ratio for heart failure for a 1 mmol/L (38.6 mg/dL) higher LDL cholesterol was 0.95 (95% CI, 0.88-1.04), which was similar after stratifying on most conventional risk factors for heart failure; however, for age below or above the median of 58 years and for presence or absence of IHD, the hazard ratios were on different sides of 1.0 (Figure 3 ). To explore whether these differences in hazard ratios for individuals with IHD could be explained mainly by individuals with premature IHD having a higher risk of developing heart failure for higher LDL cholesterol concentrations, individuals with IHD were further stratified into groups based on age at diagnosis of IHD (women <60 or >60 years and men <55 or >55 years); however, hazard ratios were similar for different age groups Ischemic heart disease 5218 (5%) 445 (5%)
Data are from the Copenhagen General Population Study from baseline at study enrollment in 2003-2014 or from the Copenhagen City Heart Study 1991-1994 examination where nonfasting triglycerides and LDL cholesterol were measured. Individuals with heart failure before baseline were excluded. Values are median and interquartile range or number of individuals and percentages. Numbers of individuals vary slightly according to availability of variables. HDL indicates high-density lipoprotein; and LDL, low-density lipoprotein.
*High alcohol intake was ≥14 drinks/week for women and ≥21 drinks/week for men (1 drink = 12 g of alcohol).
between stepwise higher nonfasting triglycerides and higher heart failure risk was similar to that found in the Copenhagen General Population Study ( Figure 1 ). Multivariable adjusted hazard ratios ranged from 1.28 (95% CI, 0.93-1.75) for nonfasting triglycerides of 1 to 1.99 mmol/L (88-175 mg/dL) to 2.33 (1.22-4.45) for nonfasting triglycerides ≥5 mmol/L (440 mg/dL) when compared with individuals with nonfasting triglycerides below 1 mmol/L (88 mg/dL). For stepwise higher LDL cholesterol, there was no association with heart failure risk, in accordance with the results from the Copenhagen General Population Study (compare Figures 1 and 4) .
Cumulative Incidence of Heart Failure for Stepwise Higher Nonfasting Triglycerides
The cumulative incidence of heart failure was higher for stepwise higher nonfasting triglycerides ( Figure 5 ). The subhazard ratios ranged from 1.17 (95% CI, 1.04-1.32) for nonfasting triglycerides 1 to 1.99 mmol/L (88-175 mg/dL) to 1.95 (1.45-2.63) for nonfasting triglycerides ≥5 mmol/L (440 mg/dL) when compared with individuals with nonfasting triglycerides below 1 mmol/L (88 mg/dL).
Nonfasting Triglycerides, LDL Cholesterol, and Heart Failure: Sensitivity Analyses
Hazard ratios for heart failure were additionally adjusted for IHD, alcohol intake, and diabetes mellitus ( Figure II in the online-only Data Supplement, left panel) and for IHD, alcohol intake, diabetes mellitus, and body mass index ( Figure II in the online-only Data Supplement, right panel). As expected, associations between higher nonfasting triglycerides and higher heart failure risk were attenuated when adjusting for these factors because nonfasting triglycerides likely are on the causal pathway from these risk factors to heart failure, that is, nonfasting triglyceride is a mediator. Also, nonfasting triglyceride is a common risk factor for both heart failure and IHD. For LDL cholesterol, there was still no association with heart failure after additional adjustments ( Figure II in the onlineonly Data Supplement).
When LDL cholesterol was multiplied by 1.43 and nonfasting triglycerides by 1.33 for individuals on lipid-lowering therapy before dividing into groups, the association between stepwise higher nonfasting triglycerides and higher heart failure risk was stronger than when triglycerides were not adjusted; however, for LDL cholesterol, there was still no association with risk of heart failure (compare Figure III in the online-only Data Supplement to Figure 1 ).
Nonfasting Triglycerides, IHD, Myocardial Infarction, and Heart Failure: Mediation Analyses
Mediation analyses were performed to assess how much of the risk of heart failure from nonfasting triglycerides could be explained by IHD and myocardial infarction ( Figure IV in the online-only Data Supplement). The proportion of effect mediated through IHD was 34% (95% CI, 26%-49%), for *High alcohol intake was ≥14 drinks/week for women and ≥21 drinks/week for men (1 drink = 12 g of alcohol).
myocardial infarction 22% (95% CI, 16%-32%), and for IHD without myocardial infarction (mainly angina pectoris) 13% (95% CI, 9%-18%).
Discussion
In 2 prospective studies of 113 554 individuals from the general population of Denmark, there was a stepwise higher risk of heart failure for stepwise higher nonfasting triglycerides; however, there was no association between LDL cholesterol and risk of heart failure. The mechanism behind higher nonfasting triglycerides being associated with higher risk of heart failure could be explained by triglycerides being a part of triglyceride-rich lipoproteins, also known as remnants, and that the cholesterol content of remnants, that is, remnant cholesterol, has been shown to be associated observationally and genetically with risk of IHD, myocardial infarction, and all-cause mortality. 11, [20] [21] [22] [23] [24] [25] Remnant cholesterol is the cholesterol content of chylomicron remnants, very low-density lipoproteins, and intermediate-density lipoproteins combined and likely is atherogenic similar to LDL cholesterol by penetrating into the arterial wall, leading to accumulation of cholesterol in the intimal space, causing foam cell formation and atherosclerosis. 11, [26] [27] [28] Also, another explanation could be triglyceride accumulation in heart muscle tissue, which in obese and diabetic individuals has been shown to cause lipotoxic cardiomyopathy and cardiac steatosis. 29 It was surprising that high concentrations of LDL cholesterol were not associated with higher risk of heart failure, neither in the Copenhagen General Population Study nor in the Copenhagen City Heart Study. In the Copenhagen General Population Study, individuals were recruited from year 2003 onwards, and it could be that individuals with high LDL cholesterol concentrations measured in the study subsequently have been treated with lipid-lowering therapy after study inclusion because participants were informed of test results from the study and may have discussed these with their general practitioner. Most general practitioners are more likely to treat high concentrations of LDL cholesterol than high concentrations of nonfasting triglycerides, why interventions on findings of high concentrations of triglycerides in the study are less likely to be treated after study inclusion. However, the findings in the Copenhagen City Heart Study, where individuals were recruited in 1991-94, are much less likely to be biased by later lipid-lowering therapy because it was less common to use these drugs in that time period. Also, it could be that remnant cholesterol and LDL cholesterol do not cause atherosclerosis and cardiovascular disease in the same way and maybe remnant cholesterol causes a more severe form of atherosclerosis, more prone to advancement into heart failure. In line with this idea, we have in a previous study found an association between high concentrations of remnant cholesterol and low-grade inflammation in addition to IHD, whereas high LDL cholesterol concentrations were not associated with inflammation, despite an association with IHD. 20 This indicated that remnant cholesterol caused atherosclerosis with an inflammatory component, while LDL cholesterol caused atherosclerosis without inflammation. Also, in a recent study, Figure 1 . Risk of heart failure for stepwise higher nonfasting triglycerides and LDL cholesterol. Observational associations were estimated in 103 860 individuals from the Copenhagen General Population Study, including 2146 events of heart failure. CI indicates confidence interval; HR, hazard ratio; and LDL, low-density lipoprotein. February 2018 high concentrations of remnant cholesterol were associated with shorter survival after a diagnosis of IHD, whereas LDL cholesterol concentrations were not. 25 This could be because of the large focus on treating LDL cholesterol concentrations in IHD patients, while high remnant cholesterol and triglyceride concentrations do not have the same focus and are, therefore, probably not treated adequately.
Why there was an association between a 1 mmol/L (38.6 mg/dL) higher LDL cholesterol and higher risk of heart failure only among individuals with IHD, and not among individuals without IHD, is not known. To further explore this, it was investigated whether individuals with premature IHD (who are likely to have familial hypercholesterolemia) had a stronger association between LDL cholesterol and heart failure Figure 2 . Risk of heart failure for a 1 mmol/L (38.6 mg/dL) higher nonfasting triglycerides stratified by other risk factors for heart failure. Observational associations were estimated in 103 860 individuals from the Copenhagen General Population Study, including 2146 events of heart failure. Number of individuals vary slightly because of availability of covariates. Age, LDL cholesterol, and HDL cholesterol are below or above the median. Before estimating the median of LDL cholesterol, concentrations were multiplied with 1.43 for users of lipidlowering therapy to account for average reductions of 33%. CI indicates confidence interval; HDL, high-density lipoprotein; and LDL, lowdensity lipoprotein.
than individuals with late-onset IHD; however, hazard ratios were similar, so this did not seem to be the explanation.
Previous studies examining associations between lipid levels and risk of heart failure have had conflicting results. Some studies have found an association between triglyceride and LDL cholesterol concentrations and risk of heart failure, like the Swedish AMORIS study of 84 740 individuals, 18 where individuals in the top quintile of triglycerides had a hazard ratio of 1.79 (95% CI, 1.63-1.97) for men and of 1.70 (95% CI, 1.46-1.98) for women when compared with men and women in the lowest triglyceride quintiles. Corresponding hazard ratios for LDL cholesterol were 2.18 (1.98-2.40) for men and 1.68 (1.45-1.95) for women. The ULSAM study (Uppsala Longitudinal Study of Adult Men) including 2321 individuals 15 also found an association between high triglyceride and LDL cholesterol concentrations, with high risk of heart failure; however, in the MESA study (Multi-Ethnic Study of Atherosclerosis) with 5688 individuals, 19 high triglyceride concentrations were only associated with risk of heart failure in individuals with diabetes mellitus. Importantly, none of Figure 3 . Risk of heart failure for a 1 mmol/L (38.6 mg/dL) higher LDL cholesterol stratified by other risk factors for heart failure. Observational associations were estimated in 103 860 individuals from the Copenhagen General Population Study, including 2146 events of heart failure. Number of individuals vary slightly because of availability of covariates. Age, triglycerides, and HDL cholesterol are below or above the median. CI indicates confidence interval; HDL, high-density lipoprotein; and LDL, low-density lipoprotein.
these studies looked at the individuals with the highest concentrations of triglycerides separately and, thereby, may have underestimated the risk of having very high triglyceride levels on risk of heart failure.
A limitation to the study is the ascertainment of heart failure diagnoses from registry data without information on the underlying cause of heart failure and without information on whether the ejection fraction was preserved or reduced in the individuals with heart failure. The use of Danish national registers for ascertainment of diagnoses of heart failure has been validated previously, showing a positive predictive value of 81%, a negative predictive value of 90%, a specificity of 99%, but a low sensitivity of 29%. 30 That is, the diagnoses of heart failure in the Danish national registers are underreported, but very specific, and it is possible that the association between nonfasting triglycerides and heart failure has been attenuated somewhat as a result of this.
A strength of the present study is the large sample size of well-characterized and well-examined individuals from the general population, with independent confirmation of results in a second cohort recruited in a different time period, without much use of lipid-lowering therapy. A limitation to the study is the observational study design where causality cannot be determined. To determine whether high concentrations of nonfasting triglycerides and remnant cholesterol cause heart failure, other types of studies are needed such as randomized clinical intervention trials examining whether lowering of triglycerides and remnant cholesterol in individuals with high concentrations will reduce heart failure risk.
Also, in this study not only high but also moderately elevated triglycerides were associated with increased risk of heart failure, and individuals with moderately elevated triglycerides could potentially also benefit from triglyceride lowering. A recent study by Ford et al 31 with data on 20 years of followup on the West of Scotland Coronary Prevention Study found that individuals originally in the pravastatin-treated arm had lower cumulative hospitalization rates for heart failure, that is, statin therapy seemed to protect against future heart failure. This gives promise to studies aimed at lowering triglycerides because pravastatin in addition to lowering LDL cholesterol also lowered triglycerides by 12% in the West of Scotland Coronary Prevention Study, which could have contributed to the later reduction in heart failure. 32 At present time, 2 large randomized placebo-controlled clinical trials are recruiting (NCT01492361; NCT02104817), and one will start recruiting 33 individuals with moderately elevated triglycerides with the aim of testing whether triglyceride lowering in individuals already on statin therapy will reduce cardiovascular disease.
In conclusion, stepwise higher concentrations of nonfasting triglycerides were associated with stepwise higher risk of heart failure; however, LDL cholesterol was not associated with heart failure risk. Our findings add to the increasing evidence pointing toward a need for large randomized clinical intervention trials examining whether triglyceride and remnant cholesterol lowering in those with high concentrations will lower the risk of cardiovascular disease and heart failure. Risk of heart failure for stepwise higher nonfasting triglycerides and LDL cholesterol-independent confirmation. Observational associations were estimated in 9694 individuals from the Copenhagen City Heart Study, including 1447 events of heart failure. CI indicates confidence interval; HR, hazard ratio; and LDL, low-density lipoprotein. Figure 5 . Cumulative incidence of heart failure for stepwise higher nonfasting triglycerides. Cumulative incidence functions were plotted by stepwise higher nonfasting triglycerides for the Copenhagen General Population Study, with death as competing events and with age as the underlying timescale. Subhazard ratios were from Fine and Gray competing risk regression. CI indicates confidence interval; and HF, heart failure.
